Sign up
Pharma Capital

ANGLE appoints leading prostate cancer surgeon Greg Shaw as scientific advisor

The AIM-listed firm said Shaw brings significant additional prostate cancer and UK NHS clinical experience to its already established Scientific Advisory Board
agreement
ANGLE said Shaw is a consultant urological surgeon at University College Hospital in London

ANGLE PLC (LON:AGL) has announced the appointment of leading NHS prostate cancer surgeon Greg Shaw as a scientific advisor to the company.

The AIM-listed firm said, joining its already established Scientific Advisory Board, Shaw brings significant additional prostate cancer and UK NHS clinical experience.

READ: ANGLE upbeat on QIAGEN collaboration ahead of poster presentation

The company said Shaw is a consultant urological surgeon at University College Hospital in London and is a clinical academic with a strong interest in prostate cancer diagnostics and treatment.

ANGLE said Shaw leads several research programmes focused on current weaknesses in the way prostate cancer is treated and is an expert in robotic surgery with a high case volume. He is known for his innovative approach and commitment to quality assurance.

Andrew Newland, founder and chief executive of ANGLE, said: “As we prepare to extend our prostate cancer work, we are delighted that we will be able to benefit from Greg Shaw’s extensive experience in this area.”

He added: “Greg’s understanding of current clinical practice in the UK and the key areas of medical need that liquid biopsy can address will help us to position Parsortix clinical applications for prostate cancer in the future.”  

 

View full AGL profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.